## Abbott India Limited (ABBOTINDIA) Stock Investment Report - December 20, 2024

**1. Company Overview:**

Abbott India Limited (ABBOTINDIA) is a pharmaceutical company listed on the Indian stock exchange on January 8, 2010.  The company operates within the Pharmaceuticals sector and holds a significant position within the Indian pharmaceutical market, known for its diverse range of healthcare products.  Further details on its market share and specific product portfolio are needed for a more comprehensive analysis.

**2. Market Data Analysis:**

| Metric                     | Value             | Notes                                                              |
|-----------------------------|--------------------|----------------------------------------------------------------------|
| Current Price              | ₹28,611.05        | Down ₹442.80 (-1.52%) from the previous close.                       |
| Percentage Change (PChange) | -1.52%            | Negative indicating a price decline.                                  |
| Pre-Open Activity          | ₹28,927           | Opened higher than the previous close but closed lower.             |
| Week High                   | ₹30,521 (Aug 30)   | Significant high compared to the current price.                     |
| Week Low                    | ₹22,000 (Dec 21)   | Significant low indicating recent volatility.                        |
| VWAP                       | ₹28,856.51        | Volume Weighted Average Price suggests a slightly higher average price. |
| Sector PE                  | NA                 | Not Available.  Requires further research.                          |
| Symbol PE                  | NA                 | Not Available. Requires further research.                          |
| Delivery Percentage        | 44.49%            | Moderate delivery percentage, suggesting a mix of long-term and short-term investors. |
| Market Depth               | Poor               | The provided market depth data (total buy/sell quantities of 0) is insufficient and needs further investigation.  This is a critical omission. |


**3. Financial Performance:**

The provided data only includes one quarter's financial results (Dec 2009 - Feb 2010). This is insufficient for a comprehensive analysis of financial performance trends.  At least five quarters of data are needed to identify growth or decline patterns and calculate key financial ratios (e.g., ROE, ROA, Debt-to-Equity).  **This is a major limitation of the analysis.**

**4. Corporate Actions and Announcements:**

Abbott India has a history of consistent dividend payouts, including special dividends.  The most recent dividend was ₹410 per share with an ex-date of July 19, 2024.  No other significant announcements are mentioned in the provided data.  However, the absence of recent announcements needs further investigation.

**5. Shareholding Patterns:**

| Date       | Promoter & Promoter Group | Public | Shares held by Employee Trusts | Total |
|------------|--------------------------|--------|-------------------------------|-------|
| 31-Dec-2017 | 74.99%                    | 25.01% | 0.00%                         | 100.00% |
| 31-Mar-2018 | 74.99%                    | 25.01% | 0.00%                         | 100.00% |
| 30-Jun-2018 | 74.99%                    | 25.01% | 0.00%                         | 100.00% |
| 30-Sep-2018 | 74.99%                    | 25.01% | 0.00%                         | 100.00% |
| 31-Dec-2018 | 74.99%                    | 25.01% | 0.00%                         | 100.00% |

Promoter holding has remained consistently high at approximately 75% over the period shown.  This suggests strong management control.  However, more recent data is needed to confirm this trend.

**6. Volatility and Risk Assessment:**

The stock shows significant volatility based on the week's high and low.  The annualized volatility of 25.79% (from marketDeptOrderBook) indicates a relatively high-risk investment.  Further analysis using historical price data and other risk metrics (e.g., Beta) is required for a more precise assessment.

**7. Advantages of Buying the Stock:**

* Consistent dividend payouts.
* High promoter holding, suggesting strong management control.
* Operates in a growing healthcare sector.

**8. Disadvantages and Risks:**

* High volatility.
* Limited financial data provided for a thorough analysis.
* Lack of market depth data.
* Dependence on the pharmaceutical sector, which is susceptible to regulatory changes and competition.


**9. Investment Horizon Recommendations:**

* **Short-term (less than 3 months): Hold.** The recent price decline and lack of clear short-term triggers make a "Buy" recommendation risky.  The high volatility further supports a "Hold" strategy until more information is available.

* **Medium-term (3 to 12 months): Hold.**  The medium-term outlook depends on the company's future financial performance and sector trends.  More financial data is crucial for a confident recommendation.

* **Long-term (1 year and beyond):  Don't Buy (with caveats).**  While the company operates in a promising sector and has a history of dividend payments, the lack of sufficient financial data and the high volatility make a long-term "Buy" recommendation premature.  Further research is needed.


**10. Stock and Analysis Scoring:**

**Stock Score (out of 10): 5.5**

* Financial Health: 3/10 (Insufficient data)
* Market Performance: 4/10 (Recent decline, high volatility)
* Volatility and Risk: 2/10 (High volatility)
* Corporate Actions & Governance: 7/10 (Consistent dividends, high promoter holding)
* Shareholding Patterns: 6/10 (Stable promoter holding)

**Analysis Score (out of 10): 4/10**

* Completeness and utilization of data: 2/10 (Significant data gaps, especially financial data and market depth)
* Accuracy and clarity of analysis: 6/10 (Analysis is clear where data is available, but limited by data gaps)
* Professional formatting: 6/10 (Report is well-formatted)


**11. Professional Recommendation Summary:**

Due to significant gaps in the provided data, particularly the lack of comprehensive financial statements and market depth information, a definitive "Buy," "Sell," or "Don't Buy" recommendation cannot be made with confidence.  The current recommendation is "Hold" for the short and medium term, and "Don't Buy" for the long term, pending further investigation and the acquisition of missing data.  The high volatility and limited information present considerable risk.  Investors should conduct thorough due diligence before making any investment decisions.
